Yesterday, FDA approved a supplemental application for Epclusa (sofosbuvir and velpatasvir), for the purpose of treating Hepatitis C Virus (HCV) in children ages 6 years and older. More details at https://t.co/DR4djDtGkl https://t.co/dJ8hbyBOzP
— Domanique Culpepper (@DomCulpepper) March 20, 2020
from Twitter https://twitter.com/DomCulpepper
March 20, 2020 at 12:07AM
via IFTTT
No comments:
Post a Comment